CA3192873A1 - Methods of treating melanocortin-4 receptor pathway-associated disorders - Google Patents
Methods of treating melanocortin-4 receptor pathway-associated disordersInfo
- Publication number
- CA3192873A1 CA3192873A1 CA3192873A CA3192873A CA3192873A1 CA 3192873 A1 CA3192873 A1 CA 3192873A1 CA 3192873 A CA3192873 A CA 3192873A CA 3192873 A CA3192873 A CA 3192873A CA 3192873 A1 CA3192873 A1 CA 3192873A1
- Authority
- CA
- Canada
- Prior art keywords
- arg
- cys
- seq
- phe
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082867P | 2020-09-24 | 2020-09-24 | |
| US63/082,867 | 2020-09-24 | ||
| PCT/US2021/052032 WO2022067086A1 (en) | 2020-09-24 | 2021-09-24 | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192873A1 true CA3192873A1 (en) | 2022-03-31 |
Family
ID=80845850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192873A Pending CA3192873A1 (en) | 2020-09-24 | 2021-09-24 | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240058414A1 (https=) |
| EP (1) | EP4216979A4 (https=) |
| JP (1) | JP2023542985A (https=) |
| KR (1) | KR20230095956A (https=) |
| CN (1) | CN116507353A (https=) |
| AR (1) | AR123603A1 (https=) |
| AU (1) | AU2021350017A1 (https=) |
| CA (1) | CA3192873A1 (https=) |
| CL (1) | CL2023000823A1 (https=) |
| CO (1) | CO2022009561A2 (https=) |
| MX (1) | MX2023003360A (https=) |
| TW (1) | TW202228760A (https=) |
| WO (1) | WO2022067086A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023308310A1 (en) * | 2022-07-12 | 2025-01-16 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
| EP4618952A2 (en) * | 2022-11-18 | 2025-09-24 | Rhythm Pharmaceuticals, Inc. | Methods for treating obesity with an mc4r agonist |
| WO2025106751A1 (en) * | 2023-11-14 | 2025-05-22 | Rhythm Pharmaceuticals, Inc. | Combinations of a potassium channel activator and an mc4r agonist and related methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2286825T3 (pl) * | 2005-07-08 | 2017-06-30 | Ipsen Pharma | Ligandy receptora melanokortyny |
| RU2020120797A (ru) * | 2013-03-15 | 2020-07-02 | Ритм Фармасьютикалз, Инк. | Пептидные композиции |
| MA43040A (fr) * | 2015-09-30 | 2018-08-08 | Univ Berlin Charite | Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4 |
-
2021
- 2021-09-24 EP EP21873549.6A patent/EP4216979A4/en active Pending
- 2021-09-24 TW TW110135665A patent/TW202228760A/zh unknown
- 2021-09-24 JP JP2023518779A patent/JP2023542985A/ja active Pending
- 2021-09-24 CA CA3192873A patent/CA3192873A1/en active Pending
- 2021-09-24 AU AU2021350017A patent/AU2021350017A1/en active Pending
- 2021-09-24 MX MX2023003360A patent/MX2023003360A/es unknown
- 2021-09-24 WO PCT/US2021/052032 patent/WO2022067086A1/en not_active Ceased
- 2021-09-24 US US18/028,117 patent/US20240058414A1/en active Pending
- 2021-09-24 KR KR1020237013822A patent/KR20230095956A/ko active Pending
- 2021-09-24 CN CN202180071771.8A patent/CN116507353A/zh active Pending
- 2021-09-24 AR ARP210102664A patent/AR123603A1/es unknown
-
2022
- 2022-07-07 CO CONC2022/0009561A patent/CO2022009561A2/es unknown
-
2023
- 2023-03-22 CL CL2023000823A patent/CL2023000823A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000823A1 (es) | 2023-09-15 |
| AU2021350017A1 (en) | 2023-05-04 |
| JP2023542985A (ja) | 2023-10-12 |
| AU2021350017A9 (en) | 2024-10-03 |
| MX2023003360A (es) | 2023-06-23 |
| US20240058414A1 (en) | 2024-02-22 |
| EP4216979A1 (en) | 2023-08-02 |
| WO2022067086A1 (en) | 2022-03-31 |
| CN116507353A (zh) | 2023-07-28 |
| EP4216979A4 (en) | 2024-11-06 |
| AR123603A1 (es) | 2022-12-21 |
| CO2022009561A2 (es) | 2022-07-19 |
| KR20230095956A (ko) | 2023-06-29 |
| TW202228760A (zh) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7752373B2 (ja) | メラノコルチン４受容体経路関連障害を治療する方法 | |
| CA3192873A1 (en) | Methods of treating melanocortin-4 receptor pathway-associated disorders | |
| US10167312B2 (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
| US20260001915A1 (en) | Methods for treating obesity with an mc4r agonist | |
| RU2785889C1 (ru) | Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4 | |
| HK40077660A (en) | Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation | |
| HK40073416A (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
| IL320947A (en) | Methods for treating obesity with an mc4r agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240920 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240920 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240920 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250919 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250919 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250924 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250924 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251124 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251125 |